Peter Heerma Net Worth

The estimated Net Worth of Peter Heerma is at least $1.41 Million dollars as of 2 October 2020. Mr. Heerma owns over 4,376 units of Retrophin stock worth over $2,963 and over the last 5 years he sold RTRX stock worth over $83,713. In addition, he makes $1,325,280 as Chief Commercial Officer at Retrophin.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Heerma RTRX stock SEC Form 4 insiders trading

Peter has made over 1 trades of the Retrophin stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 4,376 units of RTRX stock worth $83,713 on 2 October 2020.

The largest trade he's ever made was selling 4,376 units of Retrophin stock on 2 October 2020 worth over $83,713. On average, Peter trades about 1,459 units every 0 days since 2019. As of 2 October 2020 he still owns at least 42,329 units of Retrophin stock.

You can see the complete history of Mr. Heerma stock trades at the bottom of the page.

Peter Heerma biography

Peter Heerma is Chief Commercial Officer of the Company. Previously, Mr. Heerma served as Global Product General Manager for oncology and cardiovascular products at Amgen Inc., a biotechnology company, from December 2015 to September 2019. From December 2003 until November 2015, Mr. Heerma held roles of increasing responsibility at Abbott Laboratories (“Abbott”), and following Abbott’s spin-off of AbbVie, Inc., a biopharmaceutical company, at AbbVie. These roles included Senior Director of Portfolio Strategy for hepatology and nephrology, Senior Director and Asset Team Lead for HCV, diabetic nephropathy, and neuroscience development projects (all AbbVie), Director of Commercial Strategy Renal Care, International Marketing Director, Business Unit Manager of hospital products, and Product Manager for obesity and cardiovascular products (all Abbott). Mr. Heerma holds a Master of Science in European business administration and business law from the Lund University in Sweden and a Bachelor of Science in retail management and marketing from Stenden University in the Netherlands.

What is the salary of Peter Heerma?

As the Chief Commercial Officer of Retrophin, the total compensation of Peter Heerma at Retrophin is $1,325,280. There are 3 executives at Retrophin getting paid more, with Eric Dube having the highest compensation of $9,679,320.

How old is Peter Heerma?

Peter Heerma is 49, he's been the Chief Commercial Officer of Retrophin since 2019. There are 12 older and 1 younger executives at Retrophin. The oldest executive at Retrophin, Inc. is Gary Lyons, 68, who is the Independent Chairman of the Board.

What's Peter Heerma's mailing address?

Peter's mailing address filed with the SEC is C/O RETROPHIN, INC., 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO, CA, 92130.

Insiders trading at Retrophin

Over the last 12 years, insiders at Retrophin have traded over $26,547,782 worth of Retrophin stock and bought 585,006 units worth $5,991,663 . The most active insiders traders include Martin Shkreli, Ron Squarer, and Steve Aselage. On average, Retrophin executives and independent directors trade stock every 23 days with the average trade being worth of $1,651. The most recent stock trade was executed by Laura Clague on 23 November 2020, trading 7,500 units of RTRX stock currently worth $174,675.

What does Retrophin do?

Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Complete history of Mr. Heerma stock trades at Retrophin

Retrophin executives and stock owners

Retrophin executives and other stock owners filed with the SEC include:

• Eric Dube,
  President, Chief Executive Officer, Director
• Elizabeth Reed,
  Senior Vice President, General Counsel and Corporate Secretary
• Noah Rosenberg,
  Chief Medical Officer
• Peter Heerma,
  Chief Commercial Officer
• William Rote,
  Senior Vice President and Head of Research and Development
• Laura Clague,
  Chief Financial Officer, Senior Vice President
• Stephen Aselage,
  Director
• Sandra Poole,
  Independent Director
• Gary Lyons,
  Independent Chairman of the Board
• Timothy Coughlin,
  Independent Director
• Jeffrey Meckler,
  Independent Director
• John Orwin,
  Independent Director
• Roy Baynes,
  Independent Director
• Ron Squarer,
  Independent Director
• Suzanne Bruhn,
  Independent Director
• Neil F. Mc Farlane,
  Chief Operating Officer
• Jensen Margaret E Valeur,
  General Counsel
• John W Kozarich,
  Director
• Alvin Shih,
  EVP of Research & Development
• Cornelius E Golding,
  Director
• Steve Aselage,
  Director
• Martin Shkreli,
  Chief Executive Officer
• Steven Gary Richardson,
  Director
• Horacio Plotkin,
  Chief Medical Officer
• Jeffrey Paley,
  Director
• Marc L Panoff,
  Chief Financial Officer